Security
Tenax Therapeutics, Inc. Common Stock · TENX
TENXNASDAQCommon stockCurrentCIK 34956Updated Oct 28, 2026
Name history
OXYGEN BIOTHERAPEUTICS, INC. · through Sep 15, 2014SYNTHETIC BLOOD INTERNATIONAL INC · through Jun 30, 2008
TENX price & chart
Loading TradingView…
NASDAQ:TENX on TradingView ↗About the company
Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies. The Company owns global rights to develop and commercialize levosimendan, which it is developing for the treatment of PH-HFpEF, the most prevalent form of pulmonary hypertension globally, for which no product has been approved to date. For more information, visit www.tenaxthera.com. Tenax Therapeutics’ common stock is listed on The Nasdaq Stock Market LLC under the symbol “TENX”.
In the news
ATTENTION NASDAQ: TENX INVESTORS: Contact Berger Montague About a Tenax Therapeutics, Inc. Class Action Lawsuit ↗
TENX Stockholder Notice: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Class Action Lawsuit Against Tenax Therapeutics, Inc. ↗
Tenax Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference ↗
Recent filings
SCHEDULE 13G/A - filed by SPHERA FUNDS MANAGEMENT LTD. regarding TENAX THERAPEUTICS, INC.
Other Events
Items 8.01, 9.01
SCHEDULE 13G/A - filed by ING GROEP NV regarding TENAX THERAPEUTICS, INC.
Regulation FD Disclosure
Items 7.01, 9.01
SCHEDULE 13G - filed by ADAR1 Capital Management, LLC regarding TENAX THERAPEUTICS, INC.
Show 5 more recent filings
SCHEDULE 13G/A - filed by FMR LLC regarding TENAX THERAPEUTICS, INC.
SCHEDULE 13G - filed by ING GROEP NV regarding TENAX THERAPEUTICS, INC.
SCHEDULE 13G - filed by SPHERA FUNDS MANAGEMENT LTD. regarding TENAX THERAPEUTICS, INC.
SCHEDULE 13G - filed by MILLENNIUM MANAGEMENT LLC regarding TENAX THERAPEUTICS, INC.
SCHEDULE 13G/A - filed by Ikarian Capital, LLC regarding TENAX THERAPEUTICS, INC.
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 102,810,000Source | 99,784,745Source | 121,663,000Source | 105,857,000Source | 10,616,909Source | 123,178,000Source | 112,059,000Source | 14,460,264Source | 104,227,000Source | 96,686,000Source | 11,684,627Source | 3,404,709Source |
| Property, Plant and Equipment, NetUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 7,189Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 99,400,000Source | — | 118,000,000Source | 105,500,000Source | — | 118,800,000Source | 111,400,000Source | — | 97,600,000Source | 94,900,000Source | — | 2,123,682Source |
| Assets, CurrentUSD | 102,810,000Source | 99,783,628Source | 121,663,000Source | 105,857,000Source | 10,615,792Source | 123,178,000Source | 112,059,000Source | 14,459,147Source | 104,227,000Source | 96,686,000Source | 11,683,510Source | 3,208,465Source |
| Operating Lease, Right-of-Use AssetUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 179,503Source |
| Other Assets, NoncurrentUSD | — | 1,117Source | — | — | 1,117Source | — | — | 1,117Source | — | 0Source | 1,117Source | 9,552Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 6,599,000Source | 2,561,690Source | 8,073,000Source | 2,527,000Source | 1,740,837Source | 8,486,000Source | 2,768,000Source | 2,030,579Source | 7,156,000Source | 4,693,000Source | 3,586,520Source | 1,911,968Source |
| Stockholders’ equity: | ||||||||||||
| Preferred Stock, Value, IssuedUSD | 0Source | 0Source | 0Source | 0Source | — | 0Source | 0Source | — | 0Source | 0Source | — | 0Source |
| Common Stock, Value, IssuedUSD | 1,000Source | 341Source | 3,000Source | 0Source | 196Source | 2,000Source | 0Source | 0Source | 1,000Source | 0Source | 30Source | 4,584Source |
| Additional Paid in CapitalUSD | 448,124,000Source | 405,810,449Source | 514,560,000Source | 439,440,000Source | 313,503,142Source | 497,860,000Source | 434,554,000Source | 313,481,082Source | 464,524,000Source | 406,848,000Source | 305,350,830Source | 291,030,237Source |
| Retained Earnings (Accumulated Deficit)USD | -351,914,000Source | -308,587,735Source | -400,973,000Source | -336,110,000Source | -304,627,266Source | -383,170,000Source | -325,263,000Source | -301,051,593Source | -367,454,000Source | -314,855,000Source | -297,252,753Source | -289,542,080Source |
| Stockholders' Equity Attributable to ParentUSD | 96,211,000Source | 97,223,000Source | 113,590,000Source | 103,330,000Source | 8,876,000Source | 114,692,000Source | 109,291,000Source | 12,429,000Source | 97,071,000Source | 91,993,000Source | 8,098,107Source | 1,492,741Source |
| Liabilities and EquityUSD | 102,810,000Source | 99,784,745Source | 121,663,000Source | 105,857,000Source | 10,616,909Source | 123,178,000Source | 112,059,000Source | 14,460,264Source | 104,227,000Source | 96,686,000Source | 11,684,627Source | 3,404,709Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 6,599,000Source | 2,561,690Source | 8,073,000Source | 2,527,000Source | 1,740,837Source | 8,486,000Source | 2,768,000Source | 2,030,579Source | 7,156,000Source | 4,693,000Source | 3,586,520Source | 1,847,772Source |
| Accounts Payable, CurrentUSD | 5,608,000Source | 1,584,145Source | 6,795,000Source | 562,000Source | 869,656Source | 6,346,000Source | 1,839,000Source | 1,080,962Source | 6,041,000Source | 3,157,000Source | 2,073,149Source | 448,425Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | — | — | — | — | — | — | — | — | 0Source | 64,196Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 991,000Source | 977,545Source | 1,278,000Source | 1,965,000Source | 592,379Source | 2,140,000Source | 929,000Source | 536,443Source | 1,115,000Source | 1,536,000Source | 1,012,468Source | 775,045Source |
| Prepaid Expense and Other Assets, Current | —Source | — | — | —Source | — | — | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -15,716,000Source | -10,408,000Source | -52,599,000Source | -17,602,000Source | -7,710,673Source | -11,047,895Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | — | — | — | —Source | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 2,838,000Source | 4,142,000Source | 19,163,000Source | 1,125,000Source | — | — |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 305,000Source | -1,318,000Source | 2,884,000Source | 1,062,000Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -9,309,000Source | -6,967,000Source | -35,800,000Source | -14,811,000Source | -5,903,532Source | -12,012,873Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | — | 0Source | — | 0Source | 2,843Source | -2,323Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | — | — | — | — | 2,323Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 30,499,000Source | 23,563,000Source | 38,514,000Source | 99,870,000Source | 13,569,137Source | 8,554,956Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 99,369,000Source | 98,311,000Source | 117,976,000Source | 105,462,000Source | 118,755,000Source | 111,447,000Source | 97,565,000Source | 94,851,000Source | 9,792,130Source | 2,123,682Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | 0Source | 0Source | 23,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 5,500,000Source | 9,000Source | 2,800,000Source | 4,500,000Source | 2,700,000Source | 4,000,000Source | 18,800,000Source | 998,000Source | — | — |
| DepreciationUSD | — | — | — | 0Source | — | — | — | — | — | — | 7,570Source | 5,143Source |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | — | — | — | — | — | — | — | — | — | 0Source | -1,125Source | -2,901Source |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| General and Administrative ExpenseUSD | — | — | 6,478,000Source | 1,507,000Source | — | 5,671,000Source | 5,034,000Source | 5,655,000Source | 23,713,000Source | 6,785,000Source | 5,005,135Source | 5,675,231Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | — | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -15,804,000Source | -3,961,000Source | -17,803,000Source | -10,847,000Source | -15,716,000Source | -10,408,000Source | -52,599,000Source | -17,602,000Source | 7,710,673Source | -11,047,895Source |
| Operating ExpensesUSD | — | — | 16,806,000Source | 4,619,000Source | 18,784,000Source | 11,792,000Source | 16,573,000Source | 11,338,000Source | 56,385,000Source | 19,494,000Source | 8,233,941Source | 11,052,643Source |
| Other Nonoperating Income (Expense)USD | — | — | -15,000Source | 0Source | 0Source | -9,000Source | -4,000Source | 0Source | -33,000Source | 1,000Source | -547,235Source | — |
| Proceeds from Stock Options Exercised | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
income statement · annual statements
| Line item | Q4 2015 | Q4 2014 | Q3 2015 | Q3 2014 | Q2 2016 | Q2 2015 | Q1 2016 | Q1 2015 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | — | — |
| Operating Income (Loss)USD | — | — | -3,134,672Source | -2,431,398Source | -3,749,206Source | -4,143,195Source | -3,114,505Source | -2,416,373Source | -56,385,000Source | -19,494,000Source | 8,233,941Source | -11,052,643Source |
| Other Nonoperating Income (Expense)USD | — | — | 267,294Source | -849,556Source | 225,238Source | 88,291Source | 81,108Source | 291,221Source | -33,000Source | 1,000Source | -547,235Source | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 0Source | 0Source | — | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -2,868,346Source | -3,350,921Source | -3,524,372Source | -4,054,963Source | -3,034,500Source | -2,171,412Source | -52,599,000Source | -17,602,000Source | 7,710,673Source | -11,047,895Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.1Source | -0.43Source | — | -0.14Source | — | -0.08Source | -1.34Source | -1.15Source | — | — |
| Earnings Per Share, DilutedUSD per share | — | — | -0.1Source | -0.44Source | — | -0.14Source | — | -0.08Source | -1.34Source | -1.15Source | — | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 28,119,360Source | 10,260,021Source | — | 28,107,395Source | — | 27,661,499Source | 39,217,244Source | 15,271,705Source | — | — |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 28,119,360Source | 10,266,601Source | — | 28,107,395Source | — | 27,661,499Source | 39,217,244Source | 15,271,705Source | — | — |
| Additional Financial Items | ||||||||||||
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 12,650Source | 38,486Source | — | 0Source | 7,570Source | 5,143Source |
| General and Administrative ExpenseUSD | — | — | — | — | — | — | — | — | 23,713,000Source | 6,785,000Source | 5,005,135Source | 5,675,231Source |
| Interest ExpenseUSD | — | — | 968Source | 69,967Source | 404Source | 59Source | 1,103Source | 46,260Source | 0Source | 23,000Source | 23,967Source | 4,443Source |
| Interest Expense, DebtUSD | — | — | — | — | — | — | 0Source | 45,606Source | 0Source | 23,000Source | 23,967Source | 4,443Source |
| Operating ExpensesUSD | — | — | 3,134,672Source | 2,473,262Source | 3,749,206Source | 4,143,195Source | 3,114,505Source | 2,416,373Source | 56,385,000Source | 19,494,000Source | 8,233,941Source | 11,052,643Source |
| Research and Development ExpenseUSD | — | — | 1,227,190Source | 689,666Source | 2,518,588Source | 2,556,852Source | 1,745,901Source | 966,514Source | 32,672,000Source | 12,709,000Source | 3,228,806Source | 5,377,412Source |
| Total Revenue | — | — | —Source | —Source | — | —Source | — | —Source | — | — | — | — |
| Cost of Goods and Services Sold | — | — | —Source | —Source | — | —Source | — | —Source | — | — | — | — |
| Selling, General and Administrative Expense | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
| Amortization of Intangible Assets | — | — | —Source | —Source | —Source | —Source | —Source | —Source | — | — | — | — |
| Gross Profit | — | — | —Source | —Source | — | —Source | — | —Source | — | — | — | — |
| Net Income (Loss) Available to Common Stockholders, Basic | — | — | —Source | —Source | — | —Source | — | —Source | — | — | — | — |
| Preferred Stock Dividends, Income Statement Impact | — | — | —Source | —Source | — | —Source | — | —Source | — | — | — | — |
Offerings
Registration 333-294561
Filing attachments
d139658dex991.htm · 8-K · 2026-10-08
Corporate Presentation October 2026 Exhibit 99.1 Forward-Looking Statements Disclaimers Except for historical information, all of the statements, expectations and assumptions contained in this presentation are forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding our expectations about the design, enrollment, conduct, timing, and potential outcomes of the LEVEL-2 clinical trial; interpretations of clinical data from the LEVEL trial, i…
Read attachment ↗d43255dex991.htm · 8-K · 2026-09-09
EX-99.1 2 d43255dex991.htm EX-99.1 EX-99.1 LEVEL Clinical Trial Results September 09, 2026 Exhibit 99.1 Forward-Looking Statements Disclaimers Except for historical information, all of the statements, expectations and assumptions contained in this presentation are forward-looking statements. These forward-looking statements may include information concerning our clinical data, our regulatory plans, our future trial designs, and our possible or projected future business operations. Actual r…
Read attachment ↗d115761dex991.htm · 8-K · 2026-08-10
EX-99.1 2 d115761dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF TNX-103 did not meet statistical significance on the primary endpoint of improvement in 6-minute walk distance versus placebo In prespecified exploratory analyses in the overall trial population, treatment with TNX-103 resulted in a 49% greater reduction in NT-proBNP compared to placebo (nominal p<0.0001) and a redu…
Read attachment ↗d115761dex992.htm · 8-K · 2026-08-10
EX-99.2 3 d115761dex992.htm EX-99.2 EX-99.2 LEVEL Clinical Trial Topline Results August 10, 2026 Exhibit 99.2 Today’s Agenda Opening RemarksChris Giordano President and CEO LEVEL Topline ResultsStuart Rich, MD CMO KOL ThoughtsSanjiv Shah, MD Northwestern University Path ForwardChris Giordano CEO Q&AChris Giordano President and CEO Stuart Rich, MD CMO Doug Randall CBO Tom Staab CFO Sanjiv Shah, MD Northwestern University Forward-Looking Statements Disclaimers Except for historical informat…
Read attachment ↗d90330dex991.htm · 8-K · 2026-07-31
EX-99.1 2 d90330dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Tenax Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update Company expects to report topline data from Phase 3 LEVEL clinical trial in August 2026 CHAPEL HILL, N.C., July 31, 2026 (GLOBE NEWSWIRE) - Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) today reported financial results for the quarter ended June 30, 2026 and provided an update on its corporate p…
Read attachment ↗d20457dex991.htm · 8-K · 2026-07-02
EX-99.1 2 d20457dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Tenax Therapeutics Announces Late-Breaking Presentation of LEVEL Clinical Trial Data at ESC Congress 2026 Abstract recently submitted in anticipation of initial data analysis ahead of ESC Company expects to report topline LEVEL results in August CHAPEL HILL, N.C., July 2, 2026 (GLOBE NEWSWIRE) - Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”) announced today that results from the Phase 3 L…
Read attachment ↗